A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ATF / amino-terminal fragment

[Related PubMed/MEDLINE]
Total Number of Papers: 78
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ATF  (>> Co-occurring Abbreviation)
Long Form:   amino-terminal fragment
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 An ATF24 peptide-functionalized beta-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment. beta-E, CCK-8, PEG
2020 The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP. SAP, uPA
2017 Synergistic inhibitory effects of an engineered antibody-like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model. HER2, uPA, uPAR
2017 Targeted Molecular Imaging of Pancreatic Cancer with a Miniature Endoscope. IONPs
2016 Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris. uPA
2016 Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. ---
2016 Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera. SAP
2015 Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys. ATF-PEG-IONP, IO, MRI
2015 Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts. SSc
10  2015 Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231. EGFR
11  2014 A novel tumor targeting drug carrier for optical imaging and therapy. DIP, FA1, FMT, HSA, uPAR
12  2014 uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. NIR, uPA
13  2014 Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy. Pc, PDT, uPA, ZnPc
14  2013 DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging. DOT, FMT, IONPs, MSA, NIR, uPA, uPAR
15  2013 Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris. rATF
16  2013 Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. TPL
17  2013 Lanthanide-doped NaScF4 nanoprobes: crystal structure, optical spectroscopy and biodetection. DC, NPs, UC, uPA
18  2013 Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. GEM, IONPs, MRI, uPAR
19  2012 Crystal structure of the urokinase receptor in a ligand-free form. uPA, uPAR
20  2012 Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity. MMP-9, NHE1, NSLC, uPA, uPAR
21  2012 Urokinase requires NAD(P)H oxidase to transactivate the epidermal growth factor receptor. DPI, EGFR, siRNA, VSMC
22  2011 Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane. ---
23  2010 A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. BPTI, MMP, PA
24  2010 A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. called nanorods, EGFR, PEGs, scFv, uPAR
25  2009 Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism. ADAM, EGF, EGFR, HB-EGF, MMP, siRNA, VSMC
26  2009 In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor. MMP, PA, SMC, TIMP-1
27  2009 Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). SPPS, uPA, uPAR
28  2008 A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. EC, uPAR
29  2008 Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging. DOX, IO, MRI, uPA, uPAR
30  2006 Urokinase-type plasminogen activator induces proliferation in breast cancer cells. HMW-uPA, MAPK, uPA
31  2005 Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. AdmATF, EGF, hmATF, uPA
32  2005 Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). GPI, suPAR, suPAR
33  2005 Retroviral display of urokinase-binding domain fused to amphotropic envelope protein. MDCK
34  2004 Domain-dependent action of urokinase on smooth muscle cell responses. CTF, EACA, ERK, sc-uPA, SMC
35  2004 EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. EGFR, uPAR
36  2003 In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. HSA
37  2003 Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. EVT, PI3K, PLC, uPA, uPARs
38  2003 Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. DT, TER, uPA, uPAR
39  2003 The kringle stabilizes urokinase binding to the urokinase receptor. GFD, HBS, scu-PA, suPAR, WT
40  2003 The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection. GPI, HIV, uPA
41  2002 Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. MMP, PA, SMC, TIMP-1, uPA
42  2002 Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. uPA
43  2002 [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells]. ---
44  2001 Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. uPA
45  2001 cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. uPA
46  2001 In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. BPTI, SMC, uPA
47  2001 Urokinase-type plasminogen activator up-regulates its own expression by endothelial cells and monocytes via the u-PAR pathway. DFP, HUVECs, uPA, uPAR
48  2000 Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor. PE, uPAR
49  1999 Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. uPAR
50  1999 Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87). ---
51  1999 Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. HMVECs, mAb, TNF, uPA, uPAR
52  1999 Urokinase induces receptor mediated brain tumor cell migration and invasion. ECM, PA, PI-PLC, uPA
53  1998 Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. ERK1, uPA
54  1997 Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. uPA, uPAR
55  1997 Mechanisms of the development of osteoblastic metastases. GFD, uPAR
56  1997 Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. GPI, PAI-I, uPA, VN
57  1997 The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. ---
58  1997 Vitronectin binding to urokinase receptor in human breast cancer. uPAR
59  1996 Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. suPAR, uPAR
60  1996 Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. uPA
61  1996 [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]. HMW-uPA, SPDP, uPA, uPAR, UTI
62  1995 A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. CHO, uPA
63  1995 Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. uPA, UTI
64  1995 Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. LPS, PAI-1, PMA, TGF-beta, TNF-alpha
65  1995 Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. uPA, uPAR
66  1994 Backbone dynamics of a two-domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator. GFD, uPA
67  1994 Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process. OA, PAI, SF
68  1994 Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. RMSD
69  1993 Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. HLE
70  1993 Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. DAG, uPA, uPAR
71  1992 Heparin binding to the urokinase kringle domain. ---
72  1992 Selective localization of receptors for urokinase amino-terminal fragment at substratum contact sites of an in vitro-established line of human epidermal cells. GPI, uPA
73  1992 Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. BAE, bFGF, hr, IgG, PMA, uPA
74  1991 Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. HMW-uPA, pro-uPA, uPA
75  1990 Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity. uPA
76  1989 Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase. MAB 5B4, uPA
77  1988 A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. u-PA-R, uPA
78  1985 Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. ---